{"database":"ENA","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Fastqsanger.gz":["ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR301/050/SRR30113650/SRR30113650_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR301/051/SRR30113651/SRR30113651_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR301/048/SRR30113648/SRR30113648_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR301/049/SRR30113649/SRR30113649_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR301/052/SRR30113652/SRR30113652_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR301/051/SRR30113651/SRR30113651_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR301/053/SRR30113653/SRR30113653_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR301/050/SRR30113650/SRR30113650_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR301/049/SRR30113649/SRR30113649_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR301/048/SRR30113648/SRR30113648_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR301/052/SRR30113652/SRR30113652_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR301/053/SRR30113653/SRR30113653_2.fastq.gz"]},"type":"primary"},"statusCodeValue":200,"statusCode":"OK"}],"scores":null,"additional":{"omics_type":["Genomics"],"center_name":["Department of Dermatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology"],"full_dataset_link":["https://www.ebi.ac.uk/ena/browser/view/PRJNA1143462"],"scientific_name":["Homo sapiens"],"long_description":["Melanoma is a malignant tumor with a terrible prognosis. In this study, we showed regorafenib has the ability to limit the growth, invasion and metastasis of melanoma cells but to upregulate apoptosis-prompting markers (cleaved-PARP and Bax). Moreover, ERK/E2F3 signaling influences regorafenib's ability to suppress melanoma cell growth. Ultimately, regorafenib significantly inhibits tumor growth in a dose-dependent manner in vivo. Overall design: To investigate the influence of regorafenib for melanoma cell, melanoma cell SK-MEL-2 was treated regorafenib and followed performed RNA-Seq."],"repository":["ENA"],"name_synonyms":["melanoma (disease), Melanomas, Melanoma, melanoma, determination, malignant, Malignant Melanoma, chemical analysis, BAY-73-4506, BAY 73-4506, Naevocarcinoma, Whole Transcriptome Shotgun Sequencing, malignant melanoma, Cell., RNA-seq, Stivarga, assay, 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-n-methylpyridine-2-carboxamide, BAY73-4506, Malignant Melanomas, Malignant"],"description_synonyms":["melanoma (disease), Melanomas, Melanoma, melanoma, determination, malignant, Malignant Melanoma, chemical analysis, BAY-73-4506, BAY 73-4506, Naevocarcinoma, Whole Transcriptome Shotgun Sequencing, malignant melanoma, Cell., RNA-seq, Stivarga, assay, 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-n-methylpyridine-2-carboxamide, BAY73-4506, Malignant Melanomas, Malignant"],"additional_accession":[]},"is_claimable":false,"name":"RNA-Seq analysis of the effect of regorafenib on melanoma cells","description":"RNA-Seq analysis of the effect of regorafenib on melanoma cells","dates":{"last_updated":"2025-09-24","first_public":"2024-09-09"},"accession":"PRJNA1143462","cross_references":{"GEO":["GSE273844"],"taxon":["9606"]}}